

Supplementary table: Summary on the history, organ involvement, cutaneous signs, laboratories and disease severity of SLE patients at diagnosis

Disease history	
Duration(years), median (IQR)	8 (3 - 14)
Follow-up at dermatology OPD, N (%)	44 (16.7)
Positive of history of organ involvement, N (%)	
Skin	162 (61.6)
Renal	150 (57.0)
Hematology	152 (57.8)
Arthritis	49 (18.6)
Serositis	3 (1.1)
Current cutaneous sign, N (%)	
Acute cutaneous lupus erythematosus (ACLE)	12 (4.6)
Subacute cutaneous lupus erythematosus (SCLE)	2 (0.8)
Chronic cutaneous lupus erythematosus (CCLE)	31 (11.8)
Laboratory at time of diagnosis, N (%positive) and disease severity	
ANA	242 (92.4)
Homogeneous	105 (48.0)
Speckled	93 (42.3)
Nucleolar	19 (8.6)
Peripheral	3 (1.3)
Cytoplasmic	2 (0.9)
Anti-dsDNA	107 (43.7)
ESR (mm/hr), median (IQR)	29 (15 - 46)
SLEDAI-2K score, median (IQR)	0 (0 - 2)

Anti-dsDNA: Anti-double stranded DNA; ANA: Anti-nuclear antibody; ESR: Erythrocyte sedimentation rate; mm/hr: millimeters per hour (mm/hr); CLE: Cutaneous Lupus Erythematosus; IQR: Interquartile range; OPD: Outpatient department; SD: standard deviation; SLE: Systemic Lupus Erythematosus; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index 2000; USD: United States dollar.